Target Patient Population: Patients with Active Lupus Nephritis Class III-IV, +/- V

Study Overview:

Part 1: To determine whether Iptacopan (study drug)  in combination with SoC is safe and effective in patients with Class III or IV active lupus nephritis with or without co-existing class V features, assessed as achieving complete renal response (CRR) based on UPCR. 

Part 2: To evaluate a lower dose of  Iptacopan (study drug)  with SoC as an alternative to corticosteroids

Study Timeline: Anticipated patient participation is 12 Months, 14 visits to the clinic

Number of Patients Currently Active in the Trial: 0

670 Glades Rd. Suite 110 Boca Raton, FL 33431P. (561) 368-0235 | F. (561) 368-0281